Procathepsin D (pCD), a
zymogen of lysosomal aspartic
peptidase cathepsin D, overexpression is correlated with highly invasive
malignancies, including
breast cancer. Recently, different studies have shown the role of secreted pCD as
mitogen acting both in an autocrine and a paracrine manner. The aim of the present study is to examine the anti-
tumor effects elicited by a decrease in the
protein level of pCD by
ribozyme and to explore the therapeutic potential of this specific targeting. Using the mFold program, we designed seven anti-pCD
ribozymes and checked the accessibility to target pCD
mRNA by
RNase H cleavage experiment in a cell-free system. The sequences of the 4 most effective
ribozymes were cloned and stably transfected in a highly metastatic human
breast cancer cell line, MDA-MB-231, to knock down the expression of pCD. Downregulation of pCD due to
ribozyme expression was observed by Western blotting and real-time RT-PCR. Stably transfected cells with anti-pCD
ribozymes exhibited a significant lowering of in vitro invasion (p<0.001) and reduction in lung colonization potential in nude mice when compared to control
ribozyme transfected cells. We also found that downregulation of pCD by
ribozyme promotes apoptosis of MDA-MB-231 cells on serum deprivation. These results suggest that we have generated a biologically functional
ribozyme against pCD with possible therapeutic implications in
breast cancer cells.